EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED
精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO THE PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS

References are made to (i) the announcement of Extrawell Pharmaceutical Holdings Limited (the "**Company**") dated 2 December 2025 (the "**Announcement**") regarding to the entering into of the Fourth Amendment Deed in relation to the Proposed Fourth Amendments to the terms and conditions of the Bonds and (ii) the announcements of the Company dated 27 February 2026 and 29 May 2026 (the "**Extension Announcement**") regarding the extension of the Long Stop Date and delay in despatch of Circular in respect of the major transaction in relation to the transaction contemplated under the Fourth Amendment Deed. Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Announcement and the Extension Announcement.

As stated in the Extension Announcement, a Circular containing, among other things, further information on the Proposed Fourth Amendments and a notice of the SGM will be dispatched to the Shareholders as soon as practicable on or before 11 September 2026. However, as (i) additional time is required to fulfil all the Conditions Precedent contemplated under the Fourth Amendment Deed; (ii) the Company is under discussion with Starcoin regarding the further extension of the Long Stop Date; and (iii) additional time is required to prepare and finalise certain information to be included in the Circular, the despatch of the Circular will be further postponed to a date on or before 15 November 2026.

WARNING NOTICE

Shareholders and potential investors should note that the Fourth Amendment Deed is conditional upon fulfillment of all the Conditions Precedent. The agreement on the extension of the Long Stop Date and/or the satisfaction of all the Conditions Precedent may or may not materialize. Hence, the transactions contemplated under the Fourth Amendment Deed may or may not be materialized. Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 11 September 2026

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong and Ms. Wong Sau Kuen, and the independent non-executive directors are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.

* *For identification purpose only*